Cromos™ Pharma was founded in 2004 in Portland, Oregon, USA.
Cromos™ Pharma office opened in Moscow, Russia.
Soon after beginning operations in Russia, Cromos™ Pharma added operations in Ukraine.
After two years of successful growth of operations in Ukraine Cromos™ Pharma opened an office and registered a local legal entity.
Cromos™ Pharma continued to strengthen its market presence by starting activities in Lithuania.
Cromos™ Pharma started operations in Latvia with initiation of studies in dermatology.
After several steady years of expansion the second office in Russia in the city of Smolensk was established.
Cromos™ Pharma started operations in Estonia by successfully participating in an international multi-centre study in chronic heart failure.
Cromos™ Pharma continued to expand its geography and started operations in Belarus with a successful international multi-centre trial in patients with angina pectoris.Read more
Cromos™ Pharma's EU Headquarters established in Dublin, Ireland, as part of the company's further growth strategy in EU market.
Cromos™ Pharma opened an office in the capital city of Tbilisi and started to provide full service support for clinical trials in Georgia.Read more
Cromos™ Pharma initiated operations in Moldova.
Initiation of operations in Israel allow Cromos™ Pharma to expand its capabilities in running cutting-edge pharmaceutical and medical device trials.Read more
Continuing Cromos™ Pharma's strategy for geographical expansion, operations in Bulgaria were started with an arterial hypertension trial.
Including Slovak sites into an international phase III study in NSCLC marked the beginning of Cromos™ Pharma's high grade operations in this country.
Cromos™ Pharma announced the launch of operations in Czech Republic.
Cromos™ Pharma's European presence expanded further with the starting of operations in Romania.
Successful initiation of two studies in Czech Republic led to the opening of an office in Prague.Read more
The start of operations in Poland allowed Cromos™ Pharma to enter one of the most prominent Eastern European clinical trials markets.
By analyzing study population, sites’ motivation to enroll, type of disease, subjects’ barriers to participation in the studies, we developed a comprehensive system of recruitment optimization.Read more
Further geographic expansion included opening a representative office in Budapest, Hungary.Read more
Cromos™ Pharma started to provide clinical trials services in Armenia, an unsaturated area for clinical research.
Cromos™ Pharma launched its first clinical trial in Kazakhstan, an emerging clinical trial destination in Central Asia.Read more
With a new clinical operations base in South Florida, Cromos™ Pharma is poised to better serve US and international clients who seek FDA approval and access to North, Central and South America.
The opening of the new office strengthened Cromos Pharma’s position in Poland where it has been operational since 2015.
The COVID-19 pandemic dominated 2020. Cromos Pharma was proud to play its part in the fight against the virus by managing its first global clinical trial of a drug to treat severe COVID-19 infection. Throughout 2020, Cromos Pharma continued to manage successful clinical trials related to COVID-19 as well as a wide-range of other therapeutic areas.
In 2021, Cromos Pharma achieved an important milestone as it reached 10,000 patients enrolled in its oncological studies. Cromos Pharma also managed its first trial investigating a vaccine for COVID-19.
Cromos Pharma is a US based international clinical research organization (CRO) delivering fully integrated clinical research solutions in all trial phases, across a wide range of therapeutic areas.
Cromos Pharma is driven by our goal to provide clients with the highest quality services and to exceed their expectations.
Cromos Pharma leadership team brings together professionals with extensive industry experience dedicated to delivering clinical trials success.
Cromos Pharma strives to attract the best and the brightest talent to join us in our mission to accelerate drug development.